Document is current
Any future updates will be listed below
-
Authors
Kurz, Carolin https://orcid.org/0000-0003-4299-6240
Carli, Laura
Gürsel, Selim Üstün
Schrurs, Isabelle
Jethwa, Alexander
Carboni, Margherita
Bittner, Tobias
Hortsch, Sayuri
Keeser, Daniel
Brendel, Matthias
Burow, Lena
Haeckert, Jan
Koriath, Carolin A. M.
Tatò, Maia
Utecht, Julia
Papazov, Boris
Morenas-Rodriguez, Estrella
Pogarell, Oliver
Palleis, Carla
Weidinger, Endy
Stoecklein, Sophia
Levin, Johannes
Höglinger, Günter
Rauchmann, Boris-Stephan
Perneczky, Robert
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (390857198)
Helmholtz Association
Manfred-Strohscheer Stiftung
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 11 April 2025
First Online: 2 May 2025
Declarations
:
: S.H., A.J. are full-time employees of Roche Diagnostics GmbH, Penzberg, Germany, I.S. M.C. are full-time employee of Roche Diagnostics International Ltd, Rotkreuz, Switzerland and T.B. is full-time employee and stakeholder of F. Hoffmann-La Roche Ltd, Basel, Switzerland, which manufactured the blood biomarkers that were investigated in this study. C.K. has received speaker honoraria from Roche Diagnostics International Ltd, Rotkreuz, Switzerland. R.P. has received consultancy fees and speaker honoraria from Roche. G. H. serves as a consultant for Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon. All other authors report no biomedical financial interests or potential conflicts of interest.
